Intra-Arterial Alteplase Improves Recovery After Successful Thrombectomy
Adjunctive thrombolysis increased 90-day functional independence by 15% but was associated with a nearly 6% increase in mortality.
Deucravacitinib Modulates Over 2,500 Genes in Systemic Lupus Erythematosus
Transcriptomic analysis shows TYK2 inhibition reverses myeloid dysregulation and increases regulatory T-cell populations in patients with lupus.
Accelerated Deep TMS Protocols Show High Remission Rates in Depression
A randomized trial finds that 10-day accelerated deep TMS protocols achieve 42% to 50% remission rates, exceeding pharmacotherapy alone.
Testosterone Therapy Improves Sexual Function After Radical Prostatectomy
A phase 2 trial shows 12 weeks of testosterone cypionate enhances libido and body composition without triggering biochemical recurrence.
Dihydroartemisinin-Piperaquine Reduces Early Plasmodium vivax Recurrence Compared With Chloroquine
A randomized trial in Brazil shows dihydroartemisinin-piperaquine effectively prevents early malaria recurrence when primaquine is delayed.
Single Sigmoidoscopy Reduces Male Colorectal Cancer Death at 23 Years
A Norwegian trial shows a single screening sigmoidoscopy provides long-term protection for men, but mortality benefits are absent in women.
Tenecteplase Before Thrombectomy Does Not Improve Late-Window Stroke Outcomes
A phase 3 trial in patients with proximal MCA occlusions found no functional benefit to adding tenecteplase between 4.5 and 24 hours.
Digoxin Reduces Heart Failure Risk in Rheumatic Heart Disease
A randomized trial in India shows low-dose digoxin decreases the composite risk of death or worsening heart failure by 18 percent.
Small Vessel Disease Explains Reduced Thrombectomy Benefit in Older Patients
A secondary analysis of the RESILIENT trial finds that CT markers of brain frailty, not age alone, predict poor functional outcomes.
Low-Dose Digoxin Fails to Reduce Heart Failure Events in Randomized Trial
A study of 1,001 patients found targeting low serum concentrations did not significantly lower mortality or urgent hospital visits.
CDR132L Fails to Improve Ventricular Volume After Myocardial Infarction
A phase 2 trial of the microRNA-132 inhibitor CDR132L showed no significant benefit in structural or functional endpoints at six months.
Tirofiban Improves 90-Day Outcomes After Inadequate Tenecteplase Response
Adjunctive tirofiban increased the rate of functional independence in patients with non-large vessel stroke who failed to improve.